MedTrace Logo

Fluphenazine Hydrochloride for Psoriasis

NCT00929578 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-03-31

Study results available
· View outcomes & findings →

Summary

The objective of this study is to assess the safety and biologic activity of intralesional injection of fluphenazine in adult subjects with psoriasis.

Conditions

Interventions

DRUG

Fluphenazine

Intralesional injection of Fluphenazine

DRUG

Placebo

Intralesional injection of placebo

Sponsors & Collaborators

  • Immune Control

    collaborator INDUSTRY

  • Tufts Medical Center

    lead OTHER

Principal Investigators

  • Alice B. Gottlieb, M.D., PhD. · Tufts Medical Center, Department of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-11-30
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00929578 on ClinicalTrials.gov